TW202404593A - 用於治療癌症的組合療法 - Google Patents

用於治療癌症的組合療法 Download PDF

Info

Publication number
TW202404593A
TW202404593A TW112112999A TW112112999A TW202404593A TW 202404593 A TW202404593 A TW 202404593A TW 112112999 A TW112112999 A TW 112112999A TW 112112999 A TW112112999 A TW 112112999A TW 202404593 A TW202404593 A TW 202404593A
Authority
TW
Taiwan
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
prostate cancer
administered
Prior art date
Application number
TW112112999A
Other languages
English (en)
Chinese (zh)
Inventor
莎賓娜 琪亞拉 葛素利治
潔西卡 Ｓ 布朗
馬克 Ｒ 阿爾貝特拉
伊麗莎貝塔 里奧
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202404593A publication Critical patent/TW202404593A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112112999A 2022-04-07 2023-04-07 用於治療癌症的組合療法 TW202404593A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
US63/362,612 2022-04-07

Publications (1)

Publication Number Publication Date
TW202404593A true TW202404593A (zh) 2024-02-01

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112112999A TW202404593A (zh) 2022-04-07 2023-04-07 用於治療癌症的組合療法

Country Status (11)

Country Link
US (1) US20250235448A1 (enExample)
EP (1) EP4504180A1 (enExample)
JP (1) JP2025511401A (enExample)
KR (1) KR20240170956A (enExample)
CN (1) CN118973572A (enExample)
AU (1) AU2023248685A1 (enExample)
CA (1) CA3254948A1 (enExample)
IL (1) IL316016A (enExample)
MX (1) MX2024012368A (enExample)
TW (1) TW202404593A (enExample)
WO (1) WO2023194528A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325384A1 (en) * 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regimen
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Also Published As

Publication number Publication date
KR20240170956A (ko) 2024-12-05
JP2025511401A (ja) 2025-04-15
MX2024012368A (es) 2024-11-08
CA3254948A1 (en) 2023-10-12
IL316016A (en) 2024-11-01
AU2023248685A1 (en) 2024-11-14
EP4504180A1 (en) 2025-02-12
US20250235448A1 (en) 2025-07-24
WO2023194528A1 (en) 2023-10-12
CN118973572A (zh) 2024-11-15

Similar Documents

Publication Publication Date Title
JP7788114B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
KR20170131491A (ko) Ras 돌연변이와 관련된 암의 치료 방법
US20250213556A1 (en) Combination therapy for treating cancer
AU2023248685A1 (en) Combination therapy for treating cancer
CN115038447A (zh) 用于治疗癌症的组合疗法
TW202404592A (zh) 用於治療癌症之組合療法
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
WO2024088192A1 (en) An aurora a inhibitor for use in treatments of cancers
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
KR20240148328A (ko) 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
CN116600804A (zh) 用于治疗雄激素受体突变的前列腺癌的ezh2抑制疗法
WO2021224381A1 (en) Combination therapy for treating cancer